GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without Diabetes

(MedPage Today) — The number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual spending from $1.6 billion to $5.8 billion, survey data showed.
Based on an unweighted sample of nearly…